Table of Content

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Europe Humanized Mice Model Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Type (Genetic Humanized Mice Model v/s Cell-Based Humanized Mice Model)
5.2.1.1. By Cell-Based Humanized Mice Model (CD34 Humanized Mouse Models, PBMC Humanized Mouse Models, BLT Humanized Mouse Models)
5.2.2. By Application (Oncology, Immunology & Infectious Diseases, Neuroscience, Toxicology, Others)
5.2.3. By End-User (Companies {Pharmaceutical, Biotechnology, Cosmetics}, Organizations (Pharmaceutical & Biotechnology Companies, Academic & Research Institutions, Contract Research Organizations)
5.2.4. By Country
5.2.5. By Company (2022)
5.3. Market Map
5.3.1. By Type
5.3.2. By Application
5.3.3. By End-User
5.3.4. By Country
5.4. Europe: Country Analysis
5.4.1. France Humanized Mice Model Market Outlook
5.4.1.1. Market Size & Forecast
5.4.1.1.1. By Value
5.4.1.2. Market Share & Forecast
5.4.1.2.1. By Type
5.4.1.2.2. By Application
5.4.1.2.3. By End User
5.4.2. Germany Humanized Mice Model Market Outlook
5.4.2.1. Market Size & Forecast
5.4.2.1.1. By Value
5.4.2.2. Market Share & Forecast
5.4.2.2.1. By Type
5.4.2.2.2. By Application
5.4.2.2.3. By End User
5.4.3. United Kingdom Humanized Mice Model Market Outlook
5.4.3.1. Market Size & Forecast
5.4.3.1.1. By Value
5.4.3.2. Market Share & Forecast
5.4.3.2.1. By Type
5.4.3.2.2. By Application
5.4.3.2.3. By End User
5.4.4. Italy Humanized Mice Model Market Outlook
5.4.4.1. Market Size & Forecast
5.4.4.1.1. By Value
5.4.4.2. Market Share & Forecast
5.4.4.2.1. By Type
5.4.4.2.2. By Application
5.4.4.2.3. By End User
5.4.5. Spain Humanized Mice Model Market Outlook
5.4.5.1. Market Size & Forecast
5.4.5.1.1. By Value
5.4.5.2. Market Share & Forecast
5.4.5.2.1. By Type
5.4.5.2.2. By Application
5.4.5.2.3. By End User
5.4.6. Switzerland Humanized Mice Model Market Outlook
5.4.6.1. Market Size & Forecast
5.4.6.1.1. By Value
5.4.6.2. Market Share & Forecast
5.4.6.2.1. By Type
5.4.6.2.2. By Application
5.4.6.2.3. By End User
5.4.7. Netherlands Humanized Mice Model Market Outlook
5.4.7.1. Market Size & Forecast
5.4.7.1.1. By Value
5.4.7.2. Market Share & Forecast
5.4.7.2.1. By Type
5.4.7.2.2. By Application
5.4.7.2.3. By End User
5.4.8. Poland Humanized Mice Model Market Outlook
5.4.8.1. Market Size & Forecast
5.4.8.1.1. By Value
5.4.8.2. Market Share & Forecast
5.4.8.2.1. By Type
5.4.8.2.2. By Application
5.4.8.2.3. By End User
5.4.9. Sweden Humanized Mice Model Market Outlook
5.4.9.1. Market Size & Forecast
5.4.9.1.1. By Value
5.4.9.2. Market Share & Forecast
5.4.9.2.1. By Type
5.4.9.2.2. By Application
5.4.9.2.3. By End User
5.4.10. Belgium Humanized Mice Model Market Outlook
5.4.10.1. Market Size & Forecast
5.4.10.1.1. By Value
5.4.10.2. Market Share & Forecast
5.4.10.2.1. By Type
5.4.10.2.2. By Application
5.4.10.2.3. By End User
6. Market Dynamics
6.1. Drivers
6.2. Challenges
7. Market Trends & Developments
8. Competitive Landscape
8.1. Charles River Laboratories, International, Inc.
8.2. The Jackson Laboratory
8.3. Gempharmatech Co Ltd
8.4. Taconic Biosciences, Inc.
8.5. Envigo (Harlan Laboratories, Inc.)
8.6. Laboratory Corporation of America Holdings
8.7. Janvier Labs
8.8. Trans Genic, Inc.
8.9. Genoway
8.10. Creative Biolabd
9. Strategic Recommendations